Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Global Academy for Medical Education. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The American Board of Psychiatry and Neurology has reviewed the Current Psychiatry/AACP 2020 Focus on Neuropsychiatry and has approved this program as part of a comprehensive CME program, which is mandated by the ABPN as a necessary component of maintenance of certification (MOC). The activity awards 15 AMA PRA Category 1 Credits™ (including pre-conference workshops) and 8 Self-Assessment Category 1 CME credits.

Target Audience:

This activity is designed for neuropsychiatrists, child and general psychiatrists, adolescent psychiatrists, geriatric psychiatrists, nurse practitioners, physician assistants, nurses, psychologists, social workers, and other mental health professionals interested in treating patients with
neuropsychiatric disorders.

Physician Continuing Medical Education:

The Postgraduate Institute for Medicine designates this live activity for a maximum of 15 AMA PRA Category 1 Credits™ (9.5 for the general sessions and 5.5 for attending the pre-conference workshops). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 15 (9.5 for the general sessions and 5.5 for attending the pre-conference workshops) contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined and will
be indicated on your certificate.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are
thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.


After completing this activity, the participant should be better able to:

  1. Discuss the latest research on the neurobiological mechanisms and emerging treatments for depression and treatment-resistant depression.
  2. Discuss the processes by which the microbiome and gut-brain axis are operative in neuropsychiatric disorders.
  3. Discuss the bidirectional relationship between sleep disorders and neuropsychiatric disorders.
  4. Outline the spectrum of treatment modalities for sleep disorders and integrate practice guidelines for their treatment.
  5. Discuss current knowledge regarding the neuroanatomic and neurobiologic underpinnings of aggression and impulsivity.
  6. Apply evidence-based data to diagnose and manage patients with aggression and impulsivity.
  7. Identify hormones and medications that have been associated with negative consequences on fetal and neonatal brain development and functioning
  8. Frame the treatment of psychiatric disorders during pregnancy from the standpoint of reproductive safety when considering pharmacotherapies
  9. Identify multiple and patient-centered variables in treatment selection for pregnant and reproductive-aged women with psychiatric disorders
  10. Develop strategies for screening and treatment of perinatal or postpartum depression and mood episodes in women with bipolar disorder
  11. Explain the presentation and treatment of postpartum psychosis
  12. Discuss anxiety disorders in youth and their treatments
  13. Perform a differential diagnosis for attention deficit hyperactivity disorder across childhood and adolescence
  14. Evaluate current and emerging treatment strategies for attention deficit hyperactivity disorders in children



Follow Us